Boute EH, Gianolio L, Mahmmod S, Pochesci S, et al. Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study. Inflamm Bowel Dis 2026 Jan 31:izaf335. doi: 10.1093.
PMID: 41619220